Study | Country Study period Study design |
Data source | Exposure definition | Non-exposure definition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|---|---|---|---|---|---|---|---|
Källén (control exposed to ergots) 2011 |
Sweden 1995 - 2008 population based cohort propective |
The Swedish Medical Birth Register | Infants born to women who had used Almotriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). |
exposed to other treatment, sick
Infants born to women who had used Ergots drugs for migraine during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). |
1st trimester | 6 / 527 | Exposed groups of the whole study: drugs for migraine (ergots or triptans). | |
Pregnant women who attend antenatal clinics in Sweden (which the vast majority do) are interviewed by a midwife and asked about drugs used since the pregnancy started. This interview is usually made before the end of the first trimester (usually between weeks 10 and 12 of pregnancy). | ||||||||
Källén (control unexposed, disease free) 2011 |
Sweden 1995 - 2008 population based cohort propective |
The Swedish Medical Birth Register | Infants born to women who had used drugs for migraine (triptans or ergots) during pregnancy. Exposure to Almotriptan provided and considered as a separate subgroup. |
unexposed, disease free
Infants born to women who did not use drugs for migraine. |
1st trimester | 6 / 1229901 | Exposed groups of the whole study: drugs for migraine (ergots or triptans). 1229901= Total number of infants (n=1233228) - Number of infants whose mother used drugs for migraine in 1st trimester (n=3327) | |
Pregnant women who attend antenatal clinics in Sweden (which the vast majority do) are interviewed by a midwife and asked about drugs used since the pregnancy started. This interview is usually made before the end of the first trimester (usually between weeks 10 and 12 of pregnancy). |
Study | Country Study period Study design |
Data source | Case | Control | Exposition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
---|
Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;